344 related articles for article (PubMed ID: 26528707)
21. Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Tsuzuki T; Sassa N; Shimoyama Y; Morikawa T; Shiroki R; Kuroda M; Fukatsu A; Kuwahara K; Yoshino Y; Hattori R; Gotoh M
Histopathology; 2014 Mar; 64(4):484-93. PubMed ID: 24274732
[TBL] [Abstract][Full Text] [Related]
22. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.
Steven A; Leisz S; Fussek S; Nowroozizadeh B; Huang J; Branstetter D; Dougall WC; Burchardt M; Belldegrun AS; Seliger B; Pantuck A; Kroeger N
Urol Oncol; 2018 Nov; 36(11):502.e15-502.e24. PubMed ID: 30170981
[TBL] [Abstract][Full Text] [Related]
23. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
24. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
[TBL] [Abstract][Full Text] [Related]
25. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
[TBL] [Abstract][Full Text] [Related]
26. Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications.
Roussel E; Kinget L; Verbiest A; Boeckx B; Zucman-Rossi J; Couchy G; Caruso S; Baldewijns M; Joniau S; Van Poppel H; Lambrechts D; Albersen M; Beuselinck B
Acta Oncol; 2021 Nov; 60(11):1499-1506. PubMed ID: 34448678
[TBL] [Abstract][Full Text] [Related]
27. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
28. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
29. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
30. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Santoni M; Buti S; Conti A; Porta C; Procopio G; Sternberg CN; Bracarda S; Basso U; De Giorgi U; Rizzo M; Derosa L; Ortega C; Massari F; Milella M; Bersanelli M; Cerbone L; Muzzonigro G; Burattini L; Montironi R; Santini D; Cascinu S
Target Oncol; 2015 Dec; 10(4):517-22. PubMed ID: 25559290
[TBL] [Abstract][Full Text] [Related]
32. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
33. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
34. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Song Y; Huang J; Shan L; Zhang HT
Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.
Ferreira A; Alho I; Vendrell I; Melo M; Brás R; Costa AL; Sousa AR; Mansinho A; Abreu C; Pulido C; Macedo D; Pacheco T; Correia L; Costa L; Casimiro S
Oncotarget; 2016 Jul; 7(27):41380-41389. PubMed ID: 27191503
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.
Russmueller G; Moser D; Würger T; Wrba F; Christopoulos P; Kostakis G; Seemann R; Stadler V; Wimmer G; Kornek G; Psyrri A; Filipits M; Perisanidis C
Oral Oncol; 2015 Mar; 51(3):247-53. PubMed ID: 25532817
[TBL] [Abstract][Full Text] [Related]
38. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
[TBL] [Abstract][Full Text] [Related]
39. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
40. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?
Grünwald V; Merseburger AS
Eur J Cancer; 2013 Jul; 49(11):2504-11. PubMed ID: 23601669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
